Array BioPharma analyst commentary at StifelArray BioPharma price target raised to $26 at Stifel after physician survey. After surveying 45 U.S. physicians that treat metastatic melanoma patients, Stifel analyst Stephen Willey said that the survey results demonstrate a "highly-favorable competitive perception" of the Phase 3 COLUMBUS data and estimated BRAF/MEK inhibitor utilization rates. Given the survey results, he is increasing his Braftovi/Mektovi peak market share and sales estimates and raised his price target on Array Biopharma shares to $26 from $24. Willey keeps a Buy rating on Array.Read more at: https://thefly.com/landingPage...(Source theFly) * This stock has been on our trading list for a while now. Will continue to look for trades in this name. * Tiger's Take: "Reacting well today to the price target increase and the IBB/Biotech advance today. Appears to have some good potential". $ARRY, Array BioPharma Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. Follow us and check back occasionally for additional articles or posts.